KAFOCIN
LOE ApproachingNDAORALCAPSULE
Approved
Jun 1970
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 9h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
KAFOCIN is an oral small-molecule capsule approved by Eli Lilly in 1970 with an unknown mechanism of action and therapeutic indication. The product's specific clinical use cannot be determined from available data.
LOE Approaching
With LOE approaching and zero linked job openings, this mature product faces declining team investment and limited career growth opportunities.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
KAFOCIN offers zero current job opportunities and represents a legacy product in terminal decline. Career progression on this asset is severely limited, with roles focused on commercial maintenance rather than growth or innovation.
Brand ManagerField Sales Representative
Worked on KAFOCIN at Eli Lilly and Company? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.